Sanofi said it will pay MannKind as much as $925 million for the global rights to inhaled insulin Afrezza, just a couple months after the treatment received FDA approval. Afrezza is the world's only inhaled insulin, an alternative to injections for adults with diabetes. MannKind will receive an upfront payment of $150 million and milestone payments of up to $775 million, depending on the drug's commercial success. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi said the deal is the latest opportunity for the company to bring another insulin option to people with diabetes around the globe.

More from Video

Striking Options: Earnings, Gold, & Nasdaq

Striking Options: Earnings, Gold, & Nasdaq

This Market is Comparable to Getting Into a 'Fist Fight'

This Market is Comparable to Getting Into a 'Fist Fight'

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

3 Things Investors Can Do to Stay Strategic When the Market's Volatile

Is Now the Time to Be in Tech? Experts Weigh in

Is Now the Time to Be in Tech? Experts Weigh in

Canopy's CEO and Constellation Brands COO Discuss the Many Uses of Cannabis

Canopy's CEO and Constellation Brands COO Discuss the Many Uses of Cannabis